A new study based on data from a national cancer registry in Taiwan found evidence that lung cancer screening may be leading to overdiagnosis at the population level.

Faulty DNA damage repair can lead to many types of cancer, neurodegenerative diseases, and other serious disorders. MGH investigators and colleagues have developed high-throughput microscopy and machine learning systems that can identify and classify DNA repair factors. The investigators have identified nine previously unknown factors involved in the process of cellular DNA repair.

Higher coffee consumption is linked with a lower risk of endometrial cancer, a type of cancer that begins in the lining of uterus, according to an analysis of relevant studies published in the Journal of Obstetrics and Gynaecology Research.

Immunotherapy given before surgery caused liver cancer tumors to die off in one-third of the patients enrolled in a first-of-its-kind clinical trial, Mount Sinai researchers reported in The Lancet Gastroenterology & Hepatology in January.

Four MUSC Hollings Cancer Center researchers received American Cancer Society Institutional Research Grants worth $35,000 each. The grants are awarded to researchers investigating promising projects that will push cancer care forward.

An international team led by uOttawa Faculty of Medicine researchers have published findings that could contribute to future therapeutics for muscle degeneration due to old age, and diseases such as cancer and muscular dystrophy.

A mutated gene affects growth of brain tumor cells in young adults, indicating sensitivity to a new treatment strategy, a team of researchers at the University of Michigan Rogel Cancer Center discovered. These findings, recently published in Cell Reports, present possibilities for more effective therapies for glioma patients with this gene mutation.

Peptide receptor radionuclide therapy (PRRT) with lutetium dotatate is a treatment for well-differentiated neuroendocrine tumors that the U.S. Food and Drug Administration approved in 2018, but clinicians have lacked a metric for predicting its benefit on an individual patient basis. Now, a clinical score system developed by researchers at Vanderbilt-Ingram Cancer Center (VICC) has been validated that can guide PRRT treatment decisions.